newsfilter
← Earnings
Earnings Releases·

Serina Therapeutics — Third Quarter 2026 Earnings Summary

  • Total revenues reached $125,000 in Q3 2026 compared to $0 in the prior year period, while operating expenses rose to $8.0 million from $6.4 million.
  • Net loss for the quarter was $7.9 million ($0.31 per share), an improvement from $4.7 million ($0.45 per share) in 2025; cash and cash equivalents increased significantly to $19.4 million from $3.1 million at year-end 2025.
  • SER-252 advanced to Cohort 2 of its registrational Parkinson's disease study following a positive Safety Monitoring Committee review of Cohort 1 data, with blinded observations showing sustained drug exposure and motor function improvements.
  • Topline single-ascending-dose data for the SER-252 registrational study is expected in the first half of 2027, alongside plans to advance the POZ platform via out-licensing or partnership arrangements.
Company
SERINA THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology